Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.
Identifieur interne : 000F01 ( PubMed/Checkpoint ); précédent : 000F00; suivant : 000F02Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.
Auteurs : Leslie R. Harrold [États-Unis] ; George W. Reed [États-Unis] ; Daniel H. Solomon [États-Unis] ; Jeffrey R. Curtis [États-Unis] ; Mei Liu [États-Unis] ; Jeffrey D. Greenberg [États-Unis] ; Joel M. Kremer [États-Unis]Source :
- Arthritis research & therapy [ 1478-6362 ] ; 2016.
Descripteurs français
- KwdFr :
- Abatacept (usage thérapeutique), Adulte, Adulte d'âge moyen, Anticorps monoclonaux humanisés (usage thérapeutique), Antirhumatismaux (usage thérapeutique), Enregistrements, Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs), Femelle, Humains, Mâle, Polyarthrite rhumatoïde (traitement médicamenteux), Résultat thérapeutique, Score de propension, Sujet âgé, États-Unis d'Amérique.
- MESH :
- antagonistes et inhibiteurs : Facteur de nécrose tumorale alpha.
- traitement médicamenteux : Polyarthrite rhumatoïde.
- usage thérapeutique : Abatacept, Anticorps monoclonaux humanisés, Antirhumatismaux.
- Adulte, Adulte d'âge moyen, Enregistrements, Femelle, Humains, Mâle, Résultat thérapeutique, Score de propension, Sujet âgé, États-Unis d'Amérique.
English descriptors
- KwdEn :
- Abatacept (therapeutic use), Adult, Aged, Antibodies, Monoclonal, Humanized (therapeutic use), Antirheumatic Agents (therapeutic use), Arthritis, Rheumatoid (drug therapy), Female, Humans, Male, Middle Aged, Propensity Score, Registries, Treatment Outcome, Tumor Necrosis Factor-alpha (antagonists & inhibitors), United States.
- MESH :
- chemical , antagonists & inhibitors : Tumor Necrosis Factor-alpha.
- chemical , therapeutic use : Abatacept, Antibodies, Monoclonal, Humanized, Antirheumatic Agents.
- drug therapy : Arthritis, Rheumatoid.
- Adult, Aged, Female, Humans, Male, Middle Aged, Propensity Score, Registries, Treatment Outcome, United States.
Abstract
We compared the effectiveness of abatacept (ABA) vs tocilizumab (TCA) in tumor necrosis factor inhibitor (TNFi) experienced patients.
DOI: 10.1186/s13075-016-1179-7
PubMed: 27906048
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:27906048Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.</title><author><name sortKey="Harrold, Leslie R" sort="Harrold, Leslie R" uniqKey="Harrold L" first="Leslie R" last="Harrold">Leslie R. Harrold</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, AC7-201, Worcester, MA, 01655, USA. Leslie.Harrold@umassmed.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, AC7-201, Worcester, MA, 01655</wicri:regionArea><wicri:noRegion>01655</wicri:noRegion></affiliation></author><author><name sortKey="Reed, George W" sort="Reed, George W" uniqKey="Reed G" first="George W" last="Reed">George W. Reed</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, AC7-201, Worcester, MA, 01655, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, AC7-201, Worcester, MA, 01655</wicri:regionArea><wicri:noRegion>01655</wicri:noRegion></affiliation></author><author><name sortKey="Solomon, Daniel H" sort="Solomon, Daniel H" uniqKey="Solomon D" first="Daniel H" last="Solomon">Daniel H. Solomon</name><affiliation wicri:level="2"><nlm:affiliation>Brigham and Women's Hospital, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Brigham and Women's Hospital, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Curtis, Jeffrey R" sort="Curtis, Jeffrey R" uniqKey="Curtis J" first="Jeffrey R" last="Curtis">Jeffrey R. Curtis</name><affiliation wicri:level="2"><nlm:affiliation>University of Alabama at Birmingham, Birmingham, AL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Alabama at Birmingham, Birmingham, AL</wicri:regionArea><placeName><region type="state">Alabama</region></placeName></affiliation></author><author><name sortKey="Liu, Mei" sort="Liu, Mei" uniqKey="Liu M" first="Mei" last="Liu">Mei Liu</name><affiliation wicri:level="2"><nlm:affiliation>Corrona, LLC, Southborough, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Corrona, LLC, Southborough, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Greenberg, Jeffrey D" sort="Greenberg, Jeffrey D" uniqKey="Greenberg J" first="Jeffrey D" last="Greenberg">Jeffrey D. Greenberg</name><affiliation wicri:level="2"><nlm:affiliation>Corrona, LLC, Southborough, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Corrona, LLC, Southborough, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Kremer, Joel M" sort="Kremer, Joel M" uniqKey="Kremer J" first="Joel M" last="Kremer">Joel M. Kremer</name><affiliation wicri:level="2"><nlm:affiliation>Albany Medical College, Albany, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Albany Medical College, Albany, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27906048</idno><idno type="pmid">27906048</idno><idno type="doi">10.1186/s13075-016-1179-7</idno><idno type="wicri:Area/PubMed/Corpus">000C82</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C82</idno><idno type="wicri:Area/PubMed/Curation">000C82</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000C82</idno><idno type="wicri:Area/PubMed/Checkpoint">000F01</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000F01</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.</title><author><name sortKey="Harrold, Leslie R" sort="Harrold, Leslie R" uniqKey="Harrold L" first="Leslie R" last="Harrold">Leslie R. Harrold</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, AC7-201, Worcester, MA, 01655, USA. Leslie.Harrold@umassmed.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, AC7-201, Worcester, MA, 01655</wicri:regionArea><wicri:noRegion>01655</wicri:noRegion></affiliation></author><author><name sortKey="Reed, George W" sort="Reed, George W" uniqKey="Reed G" first="George W" last="Reed">George W. Reed</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, AC7-201, Worcester, MA, 01655, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, AC7-201, Worcester, MA, 01655</wicri:regionArea><wicri:noRegion>01655</wicri:noRegion></affiliation></author><author><name sortKey="Solomon, Daniel H" sort="Solomon, Daniel H" uniqKey="Solomon D" first="Daniel H" last="Solomon">Daniel H. Solomon</name><affiliation wicri:level="2"><nlm:affiliation>Brigham and Women's Hospital, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Brigham and Women's Hospital, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Curtis, Jeffrey R" sort="Curtis, Jeffrey R" uniqKey="Curtis J" first="Jeffrey R" last="Curtis">Jeffrey R. Curtis</name><affiliation wicri:level="2"><nlm:affiliation>University of Alabama at Birmingham, Birmingham, AL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Alabama at Birmingham, Birmingham, AL</wicri:regionArea><placeName><region type="state">Alabama</region></placeName></affiliation></author><author><name sortKey="Liu, Mei" sort="Liu, Mei" uniqKey="Liu M" first="Mei" last="Liu">Mei Liu</name><affiliation wicri:level="2"><nlm:affiliation>Corrona, LLC, Southborough, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Corrona, LLC, Southborough, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Greenberg, Jeffrey D" sort="Greenberg, Jeffrey D" uniqKey="Greenberg J" first="Jeffrey D" last="Greenberg">Jeffrey D. Greenberg</name><affiliation wicri:level="2"><nlm:affiliation>Corrona, LLC, Southborough, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Corrona, LLC, Southborough, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Kremer, Joel M" sort="Kremer, Joel M" uniqKey="Kremer J" first="Joel M" last="Kremer">Joel M. Kremer</name><affiliation wicri:level="2"><nlm:affiliation>Albany Medical College, Albany, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Albany Medical College, Albany, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></analytic><series><title level="j">Arthritis research & therapy</title><idno type="eISSN">1478-6362</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abatacept (therapeutic use)</term><term>Adult</term><term>Aged</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Arthritis, Rheumatoid (drug therapy)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Propensity Score</term><term>Registries</term><term>Treatment Outcome</term><term>Tumor Necrosis Factor-alpha (antagonists & inhibitors)</term><term>United States</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Abatacept (usage thérapeutique)</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Antirhumatismaux (usage thérapeutique)</term><term>Enregistrements</term><term>Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs)</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Polyarthrite rhumatoïde (traitement médicamenteux)</term><term>Résultat thérapeutique</term><term>Score de propension</term><term>Sujet âgé</term><term>États-Unis d'Amérique</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Abatacept</term><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Facteur de nécrose tumorale alpha</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Polyarthrite rhumatoïde</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Abatacept</term><term>Anticorps monoclonaux humanisés</term><term>Antirhumatismaux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Propensity Score</term><term>Registries</term><term>Treatment Outcome</term><term>United States</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Enregistrements</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Résultat thérapeutique</term><term>Score de propension</term><term>Sujet âgé</term><term>États-Unis d'Amérique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We compared the effectiveness of abatacept (ABA) vs tocilizumab (TCA) in tumor necrosis factor inhibitor (TNFi) experienced patients.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27906048</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>08</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1478-6362</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>12</Month><Day>01</Day></PubDate></JournalIssue><Title>Arthritis research & therapy</Title><ISOAbbreviation>Arthritis Res. Ther.</ISOAbbreviation></Journal><ArticleTitle>Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.</ArticleTitle><Pagination><MedlinePgn>280</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND">We compared the effectiveness of abatacept (ABA) vs tocilizumab (TCA) in tumor necrosis factor inhibitor (TNFi) experienced patients.</AbstractText><AbstractText Label="METHODS">We identified rheumatoid arthritis (RA) patients from a large observational US cohort (1 January 2010-31 May 2014) who had discontinued at least one TNFi and initiated ABA or TCZ in moderate or high disease activity based on the Clinical Disease Activity Index (CDAI) and had no prior exposure to the comparator drug. Using propensity score matching (1:1) stratified by prior TNF use (1 TNFi vs ≥2 TNFis), effectiveness at 6 months after initiation was evaluated. Mean change in CDAI over 6 months following initiation was the primary outcome, with secondary outcomes of achievement of low disease activity/remission (CDAI ≤ 10) and mean change in modified Health Assessment Questionnaire (mHAQ) score.</AbstractText><AbstractText Label="RESULTS">The 264 pairs of propensity score-matched ABA and TCZ initiators were well matched with no substantial differences in the baseline characteristics, defined as standardized differences >0.1 in the stratification. Both treatment groups had similar mean change in CDAI at 6 months (-11.3 in ABA vs -9.9 in TCZ; mean difference -1.27, 95% CI -3.65, 1.11). Similar proportions of both treatment groups achieved low disease activity/remission (adjusted odds ratio for ABA vs TCZ 0.99, 95% CI 0.69, 1.43). Mean change in mHAQ was -0.12 in ABA initiators vs -0.11 in TCZ initiations (mean difference -0.01, 95% CI -0.09, 0.06).</AbstractText><AbstractText Label="CONCLUSIONS">Patients receiving either ABA or TCZ had substantial improvement in clinical disease activity. In this propensity score-matched sample, similar outcomes were observed for both treatment cohorts.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Harrold</LastName><ForeName>Leslie R</ForeName><Initials>LR</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, AC7-201, Worcester, MA, 01655, USA. Leslie.Harrold@umassmed.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reed</LastName><ForeName>George W</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, AC7-201, Worcester, MA, 01655, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Corrona, LLC, Southborough, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solomon</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Curtis</LastName><ForeName>Jeffrey R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Mei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Corrona, LLC, Southborough, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenberg</LastName><ForeName>Jeffrey D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Corrona, LLC, Southborough, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NYU School of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kremer</LastName><ForeName>Joel M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Albany Medical College, Albany, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Rheumatology, Albany, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Arthritis Res Ther</MedlineTA><NlmUniqueID>101154438</NlmUniqueID><ISSNLinking>1478-6354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>7D0YB67S97</RegistryNumber><NameOfSubstance UI="D000069594">Abatacept</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000069594" MajorTopicYN="N">Abatacept</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057216" MajorTopicYN="N">Propensity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Abatacept</Keyword><Keyword MajorTopicYN="Y">Disease-modifying anti-rheumatic drugs (biologic)</Keyword><Keyword MajorTopicYN="Y">Rheumatoid arthritis</Keyword><Keyword MajorTopicYN="Y">Tocilizumab</Keyword><Keyword MajorTopicYN="Y">Treatment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>05</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27906048</ArticleId><ArticleId IdType="doi">10.1186/s13075-016-1179-7</ArticleId><ArticleId IdType="pii">10.1186/s13075-016-1179-7</ArticleId><ArticleId IdType="pmc">PMC5134270</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Rheumatol. 2015 Jul;42(7):1090-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25934829</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1999 Dec 4;354(9194):1932-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10622295</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2000 Nov 30;343 (22):1594-602</Citation><ArticleIdList><ArticleId IdType="pubmed">11096166</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2009 Aug 8;374(9688):459-66</Citation><ArticleIdList><ArticleId IdType="pubmed">19665644</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2016 Jul;75(7):1321-7</Citation><ArticleIdList><ArticleId IdType="pubmed">26245754</ArticleId></ArticleIdList></Reference><Reference><Citation>Biologics. 2012;6:191-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22848150</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Care Res (Hoboken). 2012 May;64(5):640-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22473918</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2010 Sep 25;376(9746):1094-108</Citation><ArticleIdList><ArticleId IdType="pubmed">20870100</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Care Res (Hoboken). 2014 Dec;66(12):1790-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24905637</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2012 Nov;71(11):1861-4</Citation><ArticleIdList><ArticleId IdType="pubmed">22736086</ArticleId></ArticleIdList></Reference><Reference><Citation>Best Pract Res Clin Rheumatol. 2005 Feb;19(1):163-77</Citation><ArticleIdList><ArticleId IdType="pubmed">15588977</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2008 Jan;58(1):15-25</Citation><ArticleIdList><ArticleId IdType="pubmed">18163481</ArticleId></ArticleIdList></Reference><Reference><Citation>J Rheumatol. 2011 Nov;38(11):2355-61</Citation><ArticleIdList><ArticleId IdType="pubmed">21885487</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2004 May;50(5):1400-11</Citation><ArticleIdList><ArticleId IdType="pubmed">15146409</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Care Res (Hoboken). 2012 May;64(5):625-39</Citation><ArticleIdList><ArticleId IdType="pubmed">22473917</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2004 Feb 28;363(9410):675-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15001324</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S172-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16273803</ArticleId></ArticleIdList></Reference><Reference><Citation>Multivariate Behav Res. 2011 May;46(3):399-424</Citation><ArticleIdList><ArticleId IdType="pubmed">21818162</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Care Res (Hoboken). 2015 Oct;67(10 ):1345-53</Citation><ArticleIdList><ArticleId IdType="pubmed">25988705</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2015 Feb;74(2):430-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24297378</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2007 May;56(5):1417-23</Citation><ArticleIdList><ArticleId IdType="pubmed">17469098</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2010 Feb;69(2):387-93</Citation><ArticleIdList><ArticleId IdType="pubmed">19416802</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2008 Jan 15;148(2):162-3</Citation><ArticleIdList><ArticleId IdType="pubmed">18195341</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2012 Sep;64(9):2824-35</Citation><ArticleIdList><ArticleId IdType="pubmed">22508468</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Alabama</li><li>Massachusetts</li><li>État de New York</li></region></list><tree><country name="États-Unis"><noRegion><name sortKey="Harrold, Leslie R" sort="Harrold, Leslie R" uniqKey="Harrold L" first="Leslie R" last="Harrold">Leslie R. Harrold</name></noRegion><name sortKey="Curtis, Jeffrey R" sort="Curtis, Jeffrey R" uniqKey="Curtis J" first="Jeffrey R" last="Curtis">Jeffrey R. Curtis</name><name sortKey="Greenberg, Jeffrey D" sort="Greenberg, Jeffrey D" uniqKey="Greenberg J" first="Jeffrey D" last="Greenberg">Jeffrey D. Greenberg</name><name sortKey="Kremer, Joel M" sort="Kremer, Joel M" uniqKey="Kremer J" first="Joel M" last="Kremer">Joel M. Kremer</name><name sortKey="Liu, Mei" sort="Liu, Mei" uniqKey="Liu M" first="Mei" last="Liu">Mei Liu</name><name sortKey="Reed, George W" sort="Reed, George W" uniqKey="Reed G" first="George W" last="Reed">George W. Reed</name><name sortKey="Solomon, Daniel H" sort="Solomon, Daniel H" uniqKey="Solomon D" first="Daniel H" last="Solomon">Daniel H. Solomon</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F01 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000F01 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:27906048
|texte= Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:27906048" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |